Ask an insurance law question, get an answer ASAP!
Click here to chat with a lawyer about your rights.

            A. As used in this Section, the following terms and phrases shall have the following meanings unless the context clearly indicates otherwise:

            (1) “Cooperative group” means a formal network of facilities that collaborate on research projects and have an established NIH-approved peer review program operating within the group. “Cooperative group” includes the following:

            (a) NCI funded clinical cooperative groups such as the Southwestern Oncology Group, Radiation Therapy Oncology Group, etc.

            (b) The NCI Community Clinical Oncology Program and its minority-based affiliates.

            (2) “FDA” means the Federal Food and Drug Administration.

            (3) “Health insurance coverage” means benefits consisting of medical care provided or arranged for directly, through insurance or reimbursement, or otherwise and including items and services paid for as medical care under any hospital or medical service policy or certificate, hospital or medical service plan contract, preferred provider organization agreement, or health maintenance organization contract offered by a health insurance issuer.

            (4) “Health insurance issuer” means an insurance company, including a health maintenance organization as defined and licensed pursuant to Subpart I of Part I of Chapter 2 of this Title, unless preempted as an employee benefit plan under the Employee Retirement Income Security Act of 1974. For purposes of this Section and Subpart B of Part II of Chapter 6 of this Title, a “health insurance issuer” shall include the Office of Group Benefits programs.

            (5) “Member” means a policyholder, subscriber, insured, or certificate holder or a covered dependent of a policyholder, subscriber, insured, or certificate holder.

            (6) “Multiple project assurance contract” means a contract between an institution and the United States Department of Health and Human Services office for protection from research risks which contract defines the relationship of the institution to the office for protection from research risks and which sets out the responsibilities of the institution and the procedures that will be used by the institution to protect human subjects.

            (7) “NCI” means the National Cancer Institute.

            (8) “NIH” means the National Institutes of Health.

            (9) “Patient” means a policyholder, subscriber, or certificate holder or a covered dependent of a policyholder, subscriber, or certificate holder.

            (10) “Patient cost” means any of the cost of health care services, treatments, or testing that are incurred as part of the protocol treatment being provided to the patient for purposes of the clinical trial. “Patient cost” shall not include the following items:

            (a) The cost of non-health care services that a patient may be required to receive as a result of the treatment being provided pursuant to the clinical trial.

            (b) Costs associated with managing the research data associated with the clinical trial.

            (c) The cost of such investigational devices or drugs not required to be covered under La. Rev. Stat. 22:999.

            (d) Costs not otherwise covered under the insured, subscriber, or enrollee’s policy, plan, or contract of coverage for noninvestigational treatments.

            B. The provisions of this Section shall apply to all health insurance coverage issued by a health insurance insurer for delivery in this state, except limited benefit and short duration health insurance policies that provide cash benefits directly to the insured when hospitalized, injured, or ill.

            C. This Section shall not apply to any policy or plan or contract paid for under Title XVII or Title X of the federal Social Security Act.

            D. Each policy or plan subject to the provisions of this Section shall provide coverage for patient costs incurred as a result of a treatment being provided in accordance with a clinical trial for cancer except any applicable copayment, deductible, or coinsurance amounts. Such costs shall include coverage for costs incurred for health-related services not otherwise required under La. Rev. Stat. 22:999.

            E. Costs of investigational treatments and costs of associated protocol-related patient care shall be covered if all of the following criteria are met:

            (1) The treatment is being provided with a therapeutic or palliative intent for patients with cancer, or for the prevention or early detection of cancer.

            (2)(a) The treatment is being provided or the studies are being conducted in a Phase I, Phase II, Phase III, or Phase IV clinical trial for cancer.

            (b) Nothing in this Section shall require a health insurance issuer offering any health insurance coverage to provide coverage for the following:

            (i) Non-healthcare services provided as part of the clinical trial.

            (ii) Costs for managing research data associated with the clinical trial.

            (iii) Investigational drugs, devices, items, or services associated with the clinical trial.

            (3) The treatment is being provided in accordance with a clinical trial approved by one of the following entities:

            (a) One of the United States NIH.

            (b) A cooperative group funded by one of the NIH.

            (c) The FDA in the form of an investigational new drug application.

            (d) The United States Department of Veterans Affairs.

            (e) The United States Department of Defense.

            (f) A federally funded general clinical research center.

            (g) The Coalition of National Cancer Cooperative Groups.

            (4) The proposed protocol has been reviewed and approved by a qualified institutional review board which operates in this state and which has a multiple project assurance contract approved by the office of protection from research risks.

            (5) The facility and personnel providing the protocol provided the treatment within their scope of practice, experience, and training and are capable of doing so by virtue of their experience, training, and volume of patients treated to maintain expertise.

            (6) There is no clearly superior, non-investigational approach.

            (7) The available clinical or preclinical data provide a reasonable expectation that the treatment will be at least as efficacious as the non-investigational alternative.

            (8) The patient has signed an institutional review board-approved consent form.

            F. Any entity seeking coverage for treatment in a clinical trial approved by an institutional review board shall post electronically, and keep up-to-date, a list of the cancer clinical trials meeting these requirements and the list shall include the following for each clinical trial:

            (1) The phase for which the trial is approved.

            (2) The entity approving the trial which renders it eligible for reimbursement.

            (3) The cancer or cancers for which the trial is approved.

            (4) The estimated number of participants in the trial.

            G. The provisions of this Section shall not be construed to affect compliance or coverage for off-label use of drugs not directly affected by this Section.

            H. The commissioner may promulgate necessary rules and regulations, pursuant to La. Rev. Stat. 22:11, to provide for submission of annual reports by health insurers describing clinical trials for which coverage was provided to insureds, subscribers, or enrollees.

            Acts 1999, No. 1357, §1, eff. July 12, 1999; Acts 2001, No. 1178, §2, eff. June 29, 2001; Redesignated from La. Rev. Stat. 22:230.4 by Acts 2008, No. 415, §1, eff. Jan. 1, 2009; Acts 2010, No. 919, §1, eff. Jan. 1, 2011; Acts 2020, No. 222, §1, eff. Jan. 1, 2021.